Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
20/11/2024 22:13
Nov 20 (Reuters) - Kura Oncology KURA.O said on
Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T
to develop and commercialize the blood cancer therapy
ziftomenib.
Kura said it will receive an upfront payment of $330 million
and up to $1.2 billion in total milestone payments as part of
the deal.
(Reporting by Christy Santhosh in Bengaluru; Editing by
Mohammed Safi Shamsi)
((Christy.Santhosh@thomsonreuters.com;))